Health care inflation rises as patients, employers brace for biggest jump in health spending in 15 years

Large employers are bracing for the largest health-care spending increase in 15 years, with projected average coverage costs rising 9% in 2026, fueled by a 4.2% annualized medical care inflation rate and significant pharmaceutical cost hikes, notably from cancer drugs and GLP-1s. This surge is prompting employers to consider passing some costs to workers as a last resort, while also exploring alternative procurement methods for high-cost medications, including leveraging cash-pay markets and pressing Pharmacy Benefit Managers (PBMs) for new payment models, signaling a potential shift in how expensive therapies are financed within employer-sponsored plans.

Analysis

Large employers are confronting the most significant health-care cost inflation in over a decade, with projections indicating a 9% average increase in coverage costs for 2026. This surge is underpinned by medical care costs rising at a 4.2% annualized rate, outpacing general inflation, and driven primarily by a projected 12% hike in pharmaceutical expenses. The main catalysts are high-cost specialty drugs, particularly cancer treatments and GLP-1 agents for obesity like Novo Nordisk's Wegovy and Eli Lilly's Zepbound. In response, employers are exploring unprecedented strategies to manage these expenses, moving beyond traditional cost-sharing with employees. A notable trend is the quiet encouragement of workers to use cash-pay markets and Health Savings Accounts for GLP-1s, evidenced by a tripling in spending at direct-to-consumer providers like Lilly Direct and Hims & Hers. This dynamic benefits GLP-1 manufacturers and DTC platforms, which are capturing strong demand through alternative channels, but it creates a structural challenge for the established Pharmacy Benefit Manager (PBM) model. The pressure from employers for new payment solutions and direct negotiation frameworks signals a potential long-term disruption in drug procurement, marking a critical 'stress test' for the entire health benefits ecosystem.

Key Decisions for Investors

• The robust and growing demand for GLP-1s, now being met through both insured and expanding cash-pay channels, reinforces a bullish outlook for manufacturers like Eli Lilly (LLY) and Novo Nordisk (NVO), suggesting their revenue streams are resilient despite payer pressures.
• Investors should recognize the significant tailwind for direct-to-consumer health companies such as Hims & Hers (HIMS), as the shift toward employer-endorsed cash-pay options for high-demand drugs creates a durable, non-traditional growth channel.
• The increasing employer pushback against Pharmacy Benefit Managers (PBMs) for better pricing and alternative models represents a material risk to the PBM industry; positions in this sub-sector should be evaluated for potential margin compression and a weakening of formulary control.
• For investors analyzing companies outside of healthcare, the projected 9% rise in employee health benefit costs should be factored into margin forecasts for 2026, as it represents a meaningful operating expense headwind for large U.S. employers.